no more gut feelings, page-2

Speculative money is entering the biotech sector. VLA will get dragged along with many other boitech hopefuls. Chart looks due for another leg up. Speculation for FDA Phase 2 approval for the melenoma injection trial will provide this next leg up.

Big money will be made if this trial is succesful but you will need patience for 1 more year to see some data after FDA approval is granted. Remember VLA market cap is about $30 million and a similar company has done a deal for $1 billion solely on excellent similar Phase 2 melenoma trial results. The big boys will be watching VLA closely.